Navigation Links
NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
Date:10/25/2007

ned from Dawson James Securities, Inc., Attn: Investment Banking, 925 South Federal Highway, 6th Floor, Boca Raton, FL 33432, telephone number (866) 928-0928. Copies of the Canadian prospectus may be obtained from Dundee Securities Corporation, 1 Adelaide St. E., Suite 2700, Toronto, Ontario M4T 1J9; Attn: Equity Capital Markets, E-mail: ecm@dundeesecurities.com.

About NovaBay

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus (MRSA). NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus and in contact lens solutions and a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay's NeutroPhase product in woundcare applications.

NovaBay(TM), Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay Pharmacuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Safe Harbor Statement

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the mar
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Corn prices and ethanol: Are the markets flaky - or working as they should?
4. Alliant to add 100 megawatts of wind power by 2005, raise gas prices
5. QBIs PreserveX product passes initial test
6. 2006: A great biotech financing year, unless you were going public!
7. TomoTherapys 100th radiology system reaches public sector
8. With patents and research tools, when is private really public?
9. Brady Corp. raises $137 million in public offering
10. In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde
11. Republican sees nothing wrong with Doyles use of executive order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... one of the interesting and challenging endeavors as ... renders highly impervious properties to the foreign substances. ... as possibility of self medication and minimal use ... low molecular weight drugs and provides specific targeting ...
(Date:8/22/2014)... 2014 The AMA is pleased to ... in Alaska that Alaska Governor Sean Parnell has signed ... defining public use of Unmanned Aircraft Systems and the ... Bill 255states that it is, “An Act relating to ... an unmanned aircraft system.” It defines State of Alaska ...
(Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... ... -, SOUTH ... of a recent Harris,Interactive(R) survey, showing that an overwhelming majority of Tracleer,patients ... their knowledge of pulmonary arterial hypertension (PAH) and,Tracleer have improved due to ...
... /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX, FSE: "HBP") today announced financial results ... HIGHLIGHTS ---------- - Subsequent to the ... CDN$16.9 million private placement of common shares, subject to ... with Dr. Donald H. Segal remaining the ...
... 17 IRIDEX,Corporation (Nasdaq: IRIX ) today ... Company as Chief Financial Officer effective January 2, ... Officer and Vice President,of Finance for NextHop Technologies, ... as Vice President of Finance and Chief,Financial Officer ...
Cached Biology Technology:Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 2Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 3Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information 4Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11IRIDEX Announces James Mackaness Will Be Chief Financial Officer 2
(Date:8/21/2014)... to ignore, but they are the ultimate source of ... are increasingly dependent on algae, too, to suck up ... to the bottom of the ocean. Now, by using ... have evidence showing that viruses infecting those algae are ... when all else stays essentially the same, and this ...
(Date:8/21/2014)... MELBOURNE, Fla. , Aug. 21, 2014 ...  announced that it has agreed to a ... Orlando,s fastest growing Certified ... make  Gabriel Health Institute  an exclusive member ... a result, Binary Biometrics will improve its ...
(Date:8/21/2014)... from Beth Israel Deaconess Medical Center (BIDMC ) are ... Influential Scientific Minds 2014," a comprehensive list ... resource for science metrics and research performance analysis. ... influential "are performing and publishing work that their peers ... according to a Thomson Reuters statement. Researchers were identified ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... spiders, and other venomous creatures, the "business end," or active ... of a protein that is most likely to undergo rapid ... Gurion University in Israel. Understanding these evolutionary forces can help ... and may also aid in the design of novel synthetic ...
... world, allocating limited health care resources as effectively and ... address that need, systems engineers at the Georgia Institute ... nations improve supply chain decisions related to the distribution ... are also forecasting what health care services would be ...
... Extensive ongoing research on biotic invasions around the world ... research in the United States shows how using improved ... plant species changes the understanding of patterns of species ... was published in the open access journal ...
Cached Biology News:Molding the business end of neurotoxins 2Engineers improve allocation of limited health care resources in resource-poor nations 2Engineers improve allocation of limited health care resources in resource-poor nations 3Human population the primary factor in exotic plant invasions in the United States 2
Request Info...
R26.4C...
... Specifications(L x W x H): 17 ... 5 5/16"18.7 lbsCapacity: 12 slidesTime: Programmable 0 ... Automated denaturation and hybridization steps 40 user ... only, and Fixed temperature) Rapid temperature ramp-up ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: